HoldsUp

FoundMyFitness · 2023-12-27 · Rhonda Patrick (host), Peter Attia

Dr. Peter Attia on Mastering Longevity – Insights on Cancer Prevention, Heart Disease, and Aging

135 research-tied claims examined: 13 contradicted 8 overstated 16 context 83 supported 15 unverified

83

Supported by research

0:05:15Peter Attiasupportedhigh

Atherosclerotic cardiovascular disease (ASCVD) is the leading cause of death in the United States and globally for both men and women.

"ASCVD, atherosclerotic cardiovascular disease, which is the leading cause of death in the United States and globally, it's leading cause of death for men and women" (said at 0:05:15)

Global and national epidemiological data confirm that atherosclerotic cardiovascular disease (ASCVD)—primarily manifest as ischemic heart disease and stroke—is the leading cause of mortality both in the United States and globally across both sexes.

0:08:30Peter Attiasupportedmoderate

Genetic conditions that compromise cholesterol synthesis are generally fatal in utero.

"there are really rare, fortunately, genetic conditions in which cholesterol synthesis is compromised, and those tend to be fatal in utero." (said at 0:08:30)

Genetic inborn errors of cholesterol biosynthesis (such as Greenberg dysplasia, severe biallelic mutations causing Smith-Lemli-Opitz syndrome, and hemizygous X-linked conditions like CHILD syndrome and Conradi-Hünermann-Happle syndrome in males) frequently result in in utero lethality, spontaneous abortion, or stillbirth, because cholesterol is vital for embryonic signaling (e.g., Hedgehog pathways) and cell membrane integrity. While hypomorphic alleles can permit live birth, they present as severe multiple congenital malformation syndromes.

0:08:55Peter Attiasupportedhigh

Testosterone, estrogen, progesterone, and cortisol are synthesized from cholesterol.

"testosterone, estrogen, progesterone, cortisol, these essential hormones are all made from cholesterol." (said at 0:08:55)

The claim is a well-established fact of human biochemistry and endocrinology. Steroid hormone biosynthesis (steroidogenesis) begins with cholesterol as the common obligate precursor. In steroidogenic tissues (such as the adrenal cortex, ovaries, and testes), cholesterol is transported into the inner mitochondrial membrane where the enzyme CYP11A1 (cholesterol side-chain cleavage enzyme / P450scc) converts it to pregnenolone. Pregnenolone is subsequently metabolized through enzymatic cascades into progesterone, cortisol (glucocorticoids), testosterone (androgens), and estradiol/estrogens.

0:10:20Peter Attiasupportedhigh

ApoB-100 is the structural apolipoprotein that sits on low-density lipoproteins (LDLs), intermediate-density lipoproteins (IDLs), and very-low-density lipoproteins (VLDLs).

"ApoB is short for apolipoprotein B-100, which is the structural apoprotein that sits on low-density lipoproteins, abbreviated LDLs; intermediate-density lipoproteins, abbreviated IDLs; very-low-density lipoproteins, abbreviated VLDLs." (said at 0:10:20)

Apolipoprotein B-100 (ApoB-100) is well-established as the primary structural apolipoprotein present on very-low-density lipoproteins (VLDL), intermediate-density lipoproteins (IDL), low-density lipoproteins (LDL), and lipoprotein(a).

0:14:10Peter Attiasupportedhigh

The Friedewald equation estimates LDL cholesterol in mg/dL as total cholesterol minus HDL cholesterol minus triglyceride concentration divided by 5.

"LDL cholesterol is estimated as total cholesterol less HDL cholesterol less triglyceride concentration divided by 5, if you're doing everything in milligrams per deciliter." (said at 0:14:10)

The speaker accurately defines the classic Friedewald equation for calculating low-density lipoprotein cholesterol (LDL-C) when lipid concentrations are measured in milligrams per deciliter (mg/dL). Under this formula, LDL-C is calculated by subtracting high-density lipoprotein cholesterol (HDL-C) and very low-density lipoprotein cholesterol (estimated as triglycerides divided by 5) from total cholesterol: LDL-C = Total Cholesterol - HDL-C - (Triglycerides / 5).

0:15:40Peter Attiasupportedmoderate

Data from the Multi-Ethnic Study of Atherosclerosis (MESA) and the Framingham Offspring study showed that LDL particle number (LDL-P) predicted cardiovascular disease risk better than LDL cholesterol (LDL-C).

"which both the MESA population, so the Multi-Ethnic Study of Atherosclerosis, and the Framingham Offspring population have both demonstrated unequivocally that when you compared LDL particle number to LDL cholesterol, LDL particle number always predicted risk better than LDL cholesterol." (said at 0:15:40)

Published observational analyses from both the Multi-Ethnic Study of Atherosclerosis (MESA) and the Framingham Offspring study support the claim. In MESA (n = 6,814), overall cardiovascular disease (CVD) hazard ratios were higher for LDL particle number (LDL-P) than for LDL cholesterol (LDL-C), and among participants with discordant LDL-P and LDL-C levels, only LDL-P was significantly associated with incident CVD events. Similarly, in the Framingham Offspring cohort (n = 3,066 followed over a median of 14.8 years), multivariable models demonstrated that LDL-P was more strongly related to future CVD events in both men and women than LDL-C.

0:21:00Peter Attiasupportedhigh

PCSK9 inhibitors lower LDL by targeting a protein that breaks down LDL receptors.

"like a PCSK9 inhibitor directly does that by targeting a protein that breaks down LDL receptors." (said at 0:21:00)

The speaker's description of the mechanism of action of PCSK9 inhibitors is accurate. Proprotein convertase subtilisin/kexin type 9 (PCSK9) is an endogenous protein that binds to cell-surface low-density lipoprotein receptors (LDLR) and directs them to lysosomes for degradation rather than recycling back to the cell surface. PCSK9 inhibitors (such as monoclonal antibodies evolocumab and alirocumab) bind and inhibit PCSK9, preventing LDLR degradation, increasing receptor density on hepatocytes, and thereby enhancing the clearance of circulating low-density lipoprotein (LDL) cholesterol.

0:23:20Peter Attiasupportedmoderate

An ApoB level of 80 mg/dL corresponds to roughly the 20th percentile in standard population reference distributions.

"the reference lab we use will say ApoB below 80 is wonderful. Well, 80 just happens to be the 20th percentile of the population." (said at 0:23:20)

In population reference cohorts (such as the Framingham Offspring Study and NHANES), standard adult distributions of apolipoprotein B (apoB) establish a median (50th percentile) concentration of approximately 100 mg/dL (1.00 g/L) with a standard deviation of approximately 24 to 26 mg/dL. In these distributions, an apoB concentration of 80 mg/dL (0.80 g/L) corresponds closely to the 20th percentile of the population.

0:27:20Peter Attiasupportedmoderate

ApoB levels rise with age.

"ApoB rises with age, right?" (said at 0:27:20)

Epidemiological and population surveillance data confirm that circulating apolipoprotein B (ApoB) concentrations increase with age. Data from the National Health and Nutrition Examination Survey (NHANES III), representing the general United States population, show that ApoB levels are lowest in childhood (averaging ~0.80 g/L) and rise progressively into adulthood (averaging ~1.2 g/L).

0:09:40Peter Attiasupportedhigh

ApoB-48 is the structural apolipoprotein that wraps chylomicrons.

"there's also an ApoB-48 that wraps another type of lipoprotein called a chylomicron." (said at 0:09:40)

The statement is fully supported by lipid biochemistry literature. Apolipoprotein B-48 (apoB-48) is produced in enterocytes of the small intestine via RNA editing of the APOB transcript and functions as the obligatory structural apolipoprotein that forms the core framework/scaffold of dietary chylomicrons and their remnants.

0:10:05Peter Attiasupportedhigh

ApoA apolipoproteins wrap the high-density lipoprotein (HDL) family of particles.

"The ApoA—and this is big A, never to be confused with Apo little a, which we may talk about—those wrap the family of high-density lipoproteins." (said at 0:10:05)

The statement is fully supported by established lipoprotein biochemistry and structural biology. Apolipoprotein A proteins—primarily ApoA-I and ApoA-II—serve as the principal structural apolipoproteins that wrap around and stabilize the lipid core of high-density lipoprotein (HDL) particles via amphipathic alpha-helices. The speaker's clarification distinguishing ApoA from apolipoprotein(a) [Apo(a), the glycoprotein component of lipoprotein(a)] is also biochemically accurate.

0:35:34Peter Attiasupportedmoderate

An ApoB level of 60 mg/dL represents approximately the 5th percentile at the adult population level.

"60 milligrams per deciliter is about the fifth percentile at the adult population level." (said at 0:35:34)

Population-level reference distributions from large cohorts (such as the National Health and Nutrition Examination Survey [NHANES]) demonstrate that an apolipoprotein B (apoB) level of approximately 60 mg/dL corresponds to the lower end of the adult population distribution (approximately the 5th percentile), aligning with an equivalent LDL-C level of approximately 70 mg/dL in untreated adults.

0:35:54Peter Attiasupportedhigh

ApoB, insulin resistance, hypertension, and smoking are the four primary causal drivers of atherosclerotic cardiovascular disease.

"So there are really four big things that are driving risk causally: ApoB is one, insulin resistance is one, hypertension is one, and smoking is one. Those are the big four. So you have to take everything we're saying on the ApoB front and acknowledge that those other things are also causally linked to ASCVD." (said at 0:35:54)

Extensive epidemiological, randomized controlled trial, and Mendelian randomization evidence confirms that elevated apolipoprotein B (ApoB)-containing lipoproteins, hypertension (elevated blood pressure), cigarette smoking, and insulin resistance/type 2 diabetes are major causal drivers of atherosclerotic cardiovascular disease (ASCVD).

0:39:50Peter Attiasupportedhigh

Carbohydrate restriction, specifically of refined and starchy carbohydrates, is the most effective dietary pattern for reducing triglycerides.

"It's pretty clearly observed from a dietary pattern perspective that carbohydrate restriction is the most effective tool at triglyceride reduction." (said at 0:39:50)

Randomized clinical trials and meta-analyses demonstrate that carbohydrate-restricted dietary patterns (including low-carbohydrate and ketogenic diets) effectively lower serum triglyceride levels compared to high-carbohydrate or standard low-fat diets. Network meta-analyses evaluating multiple dietary patterns confirm that carbohydrate restriction is among the most effective dietary interventions for triglyceride reduction and lipid modulation.

0:41:05Peter Attiasupportedmoderate

Excess saturated fat intake inhibits sterol regulatory element-binding proteins in the liver, leading to fewer LDL receptors being produced.

"I think a bigger part of it might be that excess saturated fat inhibits the sterol-binding—the sterol regulatory binding protein in the liver that results in fewer LDL receptors being made." (said at 0:41:05)

Dietary saturated fatty acids (SFAs) reduce hepatic low-density lipoprotein receptor (LDLR) gene expression and activity through modulation of the sterol regulatory element-binding protein (SREBP) pathway. Because transcription of the LDLR gene is directly controlled by active SREBP (predominantly SREBP-2), saturated fat-induced downregulation or inhibition of SREBP signaling leads to reduced LDLR production and clearance of circulating LDL particles, raising plasma LDL-cholesterol.

0:48:48Peter Attiasupportedhigh

Dr. Helen Hobbs discovered in the early to mid-2000s that individuals with loss-of-function/hypofunctioning mutations in the PCSK9 gene have LDL cholesterol levels around 10 to 20 mg/dL and are protected against cardiovascular disease.

"So Helen Hobbs made this discovery in probably the early 2000s, my vague recollection... which is, 'Hey, there are these people walking around with LDL-C of like 10 to 20 milligrams per deciliter.' ... And these people were found to have a mutation in their PCSK9 gene that rendered a hypofunctioning protein, and PCSK9 is a protein that degrades LDL receptors... and what was interesting to note is that they just didn't develop cardiovascular disease." (said at 0:48:48)

Helen Hobbs and Jonathan Cohen's team at UT Southwestern discovered in 2005–2006 that loss-of-function mutations in the PCSK9 gene cause substantial lifelong reductions in LDL cholesterol and substantial protection against coronary heart disease. In the Atherosclerosis Risk in Communities (ARIC) study, individuals with nonsense mutations had an 88% reduction in coronary heart disease risk, and compound heterozygotes lacking functional PCSK9 were identified with circulating LDL cholesterol levels as low as 14 mg/dL while remaining in good cardiovascular and general health.

0:51:40Peter Attiasupportedmoderate

Mendelian randomization studies show no causal association between low LDL cholesterol and increased cancer incidence.

"There's a clear association in the epidemiology—it doesn't come up often, but it's come up from time to time—that the lower the LDL cholesterol, the higher the risk of cancer. This is a great example of when Mendelian randomization becomes very valuable... does that have any bearing on cancer outcome? And the answer is unequivocally no, it does not." (said at 0:51:40)

Mendelian randomization (MR) analyses demonstrate that genetically determined low LDL cholesterol is not causally associated with an increased risk of cancer. While observational epidemiology frequently detects an inverse association between measured circulating LDL-C and cancer risk (largely attributed to reverse causality, where preclinical malignancy lowers circulating lipids), instrumental variable genetic analyses instrumenting lifelong low LDL-C via variants such as PCSK9, ABCG8, and APOE find no causal increase in cancer incidence.

0:57:25Peter Attiasupportedhigh

Statins lower LDL by inhibiting the rate-limiting first committed step in hepatic cholesterol synthesis, which upregulates LDL receptors on hepatocytes.

"They work by inhibiting the first committed step of cholesterol synthesis. They do that everywhere, but primarily in the liver. And the response of the liver when cholesterol synthesis is being shut down, the liver says, 'I got to get more cholesterol in here.' And what does it do? It puts a whole bunch more LDL receptors all over the liver, and that's what's primarily driving down LDL in the presence of a statin." (said at 0:57:25)

The speaker accurately describes the established mechanism of action for statin medications. Statins competitively inhibit 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase, the rate-limiting and committed enzyme in cholesterol biosynthesis, primarily within hepatocytes. The resulting decrease in intracellular cholesterol triggers a compensatory homeostatic pathway (via sterol regulatory element-binding protein 2, or SREBP-2) that upregulates LDL receptor expression on the hepatocyte membrane, increasing clearance of circulating LDL particles and lowering serum LDL cholesterol.

0:48:24Peter Attiasupportedhigh

The clinical phenotypic criteria for familial hypercholesterolemia includes an untreated LDL cholesterol level greater than 190 mg/dL.

"The phenotype is defined as having an LDL cholesterol off medication of more than 190 milligrams per deciliter, and there's a couple of other criteria, but just to give you a sense of how high the LDL needs to be to meet that criteria." (said at 0:48:24)

Clinical diagnostic criteria and screening frameworks for familial hypercholesterolemia (FH)—such as the Simon Broome register criteria, the Dutch Lipid Clinic Network criteria, and major clinical guidelines—use an untreated (off-medication) low-density lipoprotein cholesterol (LDL-C) threshold of ≥190 mg/dL (4.9 mmol/L) in adults as a primary phenotypic hallmark alongside personal/family history and physical signs.

0:57:40Peter Attiasupportedhigh

The first statin medication was developed and introduced in 1987.

"So it really wasn't until the mid to late '80s, probably I think 1987 if my memory serves me correctly, that the first statin came to be developed." (said at 0:57:40)

The speaker's statement is accurate. Lovastatin (Mevacor) was the first statin medication approved and introduced for clinical use in 1987.

0:58:05Peter Attiasupportedhigh

There are currently seven distinct statin medications approved and in clinical existence.

"So there are currently seven statins in in existence, uh, and each of them, you know, offers some strengths and advantages over others." (said at 0:58:05)

There are currently seven statin medications (HMG-CoA reductase inhibitors) approved and available for clinical use: atorvastatin, fluvastatin, lovastatin, pitavastatin, pravastatin, rosuvastatin, and simvastatin (an eighth, cerivastatin, was withdrawn from the global market in 2001). Each agent possesses distinct pharmacokinetic, lipophilicity, and metabolic profiles.

1:00:11Rhonda Patrick (host)supportedhigh

The mevalonate/HMG-CoA pathway targeted by statins for cholesterol synthesis is also required for the endogenous synthesis of coenzyme Q10 (ubiquinol).

"statins are affecting the HMG-CoA pathway that you mentioned, the cholesterol synthesis, with which also is important for the synthesis of, uh, ubiquinol, right? This is an important or CoQ10, as I should probably call it, um, this is important for mitochondrial function." (said at 1:00:11)

The host's statement is fully supported by established biochemical and clinical literature. 3-Hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase is the rate-limiting enzyme of the mevalonate pathway, which produces farnesyl pyrophosphate (FPP). FPP is a required precursor for both cholesterol biosynthesis and the polyisoprenoid tail of coenzyme Q10 (ubiquinone/ubiquinol). By inhibiting HMG-CoA reductase, statins reduce endogenous synthesis of both cholesterol and coenzyme Q10, a vital component of the mitochondrial electron transport chain.

1:02:48Peter Attiasupportedmoderate

As ATP demand on a cell increases, aging and disease lead to an earlier shift from oxidative phosphorylation to glycolysis.

"This is one of the hallmarks of health, and by extension one of the hallmarks of aging and one of the hallmarks of disease is an inability to do that, meaning as the ATP demand on a cell goes up, there is an earlier and earlier shift to glycolysis as opposed to oxidative phosphorylation." (said at 1:02:48)

A primary hallmark of cellular aging and chronic metabolic disease is mitochondrial dysfunction and reduced oxidative phosphorylation capacity. As a result of decreased mitochondrial reserve and respiratory efficiency, cells from aging or diseased tissues shift reliance toward glycolysis earlier to meet increasing energetic and ATP demands.

1:04:38Peter Attiasupportedhigh

Metformin impairs mitochondrial complex I.

"Metformin, which is a mitochondrial toxin, right? Metformin impairs complex I of the mitochondria." (said at 1:04:38)

The claim is supported. Inhibition of mitochondrial respiratory complex I (NADH:ubiquinone oxidoreductase) is a well-established primary molecular mechanism of metformin. Structural studies using cryo-electron microscopy and kinetic assays demonstrate that metformin enters mitochondrial complex I and traps at the ubiquinone binding site, leading to mild, reversible inhibition of respiratory chain activity. This complex I inhibition in intestinal and hepatic tissues is central to metformin's downstream therapeutic metabolic effects, including AMP-activated protein kinase (AMPK) activation and altered glucose regulation.

1:06:44Peter Attiasupportedmoderate

Clinical trials evaluating ubiquinol or CoQ10 supplementation in statin users have shown no difference in reducing the incidence of statin-associated muscle soreness.

"There have been a number of clinical trials looking at using or supplementing ubiquinol with patients taking statins. They have mostly done this to assess, uh, the muscle soreness issue. So they've mostly done this as a way to ask the question: can you reduce the insulin the the incidence, rather, of muscle soreness with statins? I haven't looked at those literature in a couple of years. The last I looked at them, there was still no difference." (said at 1:06:44)

The speaker accurately summarizes the predominant finding from meta-analyses and clinical literature assessing Coenzyme Q10 (CoQ10) or ubiquinol for statin-associated muscle symptoms (SAMS). Multiple meta-analyses of randomized controlled trials (RCTs) (such as Mayo Clinic Proceedings 2015, Atherosclerosis 2020, and Irish Journal of Medical Science 2022) have concluded that CoQ10 supplementation shows no statistically significant benefit over placebo in reducing muscle pain intensity or statin-induced myopathy. While some smaller or newer individual reviews (e.g., JAHA 2018 or Journal of Nutritional Science 2025) noted minor pain reductions, the overall high-quality synthesis of clinical trials shows inconsistent results with several major meta-analyses finding no significant overall difference.

1:15:39Peter Attiasupportedhigh

There has never been a clinical study evaluating statin use that had the incidence of Alzheimer's disease or dementia as a primary outcome.

"there has never been a study done that has looked at the use of statins and the incidence of Alzheimer's disease or dementia as a primary outcome." (said at 1:15:39)

Published randomized clinical trials evaluating statin therapy were primarily designed to assess cardiovascular and cerebrovascular outcomes (such as coronary events, stroke, and vascular mortality). Cognitive endpoints or incident dementia cases were evaluated only as secondary outcomes, exploratory endpoints, or in post-hoc analyses in large cardiovascular trials (e.g., the Heart Protection Study and PROSPER). Systematic reviews, including Cochrane reviews, confirm that completed randomized prevention trials evaluated individuals selected for vascular disease risk where dementia incidence was not the primary outcome, and treatment trials in established Alzheimer's disease evaluated cognitive scale changes (such as ADAS-Cog) rather than incident dementia.

1:15:55Peter Attiasupportedhigh

Clinical trials that measured dementia or Alzheimer's disease as secondary outcomes consistently found neutral to beneficial effects of statin use on dementia and Alzheimer's disease incidence.

"There are more than a dozen, probably less than 25—so a big number of studies, call it 15, 16—that have used statins, have had a primary outcome of ASCVD, but a secondary outcome of dementia or Alzheimer's disease. And I looked at every single one of those, and I can tell you that every single one of those found neutral to benefit of statin use on the incidence of dementia and the incidence of Alzheimer's disease." (said at 1:15:55)

Randomized controlled trials evaluating cardiovascular outcomes with secondary measures of cognitive function and dementia incidence have consistently demonstrated neutral effects (with no evidence of increased risk or cognitive harm, and occasional point estimates favoring benefit). Meta-analyses of randomized trials encompassing over 100,000 participants show that statins and other lipid-lowering therapies have a neutral effect on incident dementia and cognitive decline (OR ~0.90 to 1.00), refuting concerns that statin therapy accelerates cognitive decline or increases dementia incidence.

1:17:13Peter Attiasupportedmoderate

Clinical trial evidence shows no difference between lipophilic (hydrophobic) and hydrophilic statins with respect to dementia and Alzheimer's disease outcomes.

"there was no difference between hydrophobic and hydrophilic statins with respect to these outcomes. No difference whatsoever." (said at 1:17:13)

Evidence from large clinical cohorts and systematic reviews shows no meaningful difference in dementia or Alzheimer's disease risk between lipophilic and hydrophilic statins. A 2022 systematic review and meta-analysis found similar risk reductions for both lipophilic and hydrophilic statins regarding dementia and Alzheimer's disease. Similarly, an analysis of 18,846 older adults followed for cognitive decline and incident dementia found no significant differences in cognitive outcomes or dementia subclassifications between hydrophilic and lipophilic statin classes.

1:23:07Peter Attiasupportedhigh

PCSK9 inhibitors were first approved in 2015.

"So they were approved in 2015, and we have long-term data with them at—" (said at 1:23:07)

The first PCSK9 inhibitors, alirocumab (Praluent) and evolocumab (Repatha), received regulatory approvals for clinical use from both the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA) in 2015.

1:24:34Peter Attiasupportedhigh

Ezetimibe upregulates hepatic LDL receptors by inhibiting intestinal cholesterol reabsorption transporters.

"ezetimibe also effectively serves to increase the LDL receptors on the liver, but it does so by impairing cholesterol reabsorption. So it blocks one of those two transporters I was talking about in the gut, the first one. And by blocking that, the body is absorbing way less of its own cholesterol, and the liver senses that and the liver says, "Hey, I got to get more cholesterol," puts more LDL receptors on, pulls it out of circulation." (said at 1:24:34)

Ezetimibe selectively inhibits the Niemann-Pick C1-Like 1 (NPC1L1) transporter in the small intestine, blocking dietary and biliary cholesterol absorption. The resulting reduction in chylomicron cholesterol delivery to the liver depletes hepatic cholesterol pools, triggering a compensatory upregulation of hepatic low-density lipoprotein (LDL) receptors that enhances the clearance of circulating LDL cholesterol.

1:28:03Peter Attiasupportedhigh

Bempedoic acid is a prodrug that is inactive until metabolized by the liver, exerting its cholesterol synthesis inhibition exclusively within hepatocytes without affecting extrahepatic cells.

"That is a prodrug, so it's a very elegant drug. It's taken as a pill, but it's ineffective until it's metabolized by the liver, and in the liver it then inhibits cholesterol synthesis. What makes this drug special is unlike statins, this drug only works in the liver. So statins work throughout the body; they do most of their work in the liver, but technically every cell is impacted by a statin. Only hepatocytes are impacted by bempedoic acid." (said at 1:28:03)

Bempedoic acid (ETC-1002) is indeed an orally administered prodrug that requires metabolic conversion to bempedoyl-CoA by very long-chain acyl-CoA synthetase-1 (ACSVL1, encoded by SLC27A2). Because ACSVL1 is expressed primarily in hepatocytes and is absent in skeletal muscle and most peripheral tissues, bempedoic acid is activated and inhibits ATP-citrate lyase (ACLY) specifically in the liver to block cholesterol biosynthesis, unlike statins which inhibit HMG-CoA reductase throughout peripheral tissues.

1:23:15Peter Attiasupportedhigh

High intake of plant sterols (phytosterols) reduces total cholesterol absorption by outcompeting cholesterol at enterocytes in the gut.

"If you ingest a ton of phytosterols, you will outcompete cholesterol at that enterocyte, and your body will regulate and you'll end up net reabsorbing less total cholesterol." (said at 1:23:15)

Substantial human clinical trials and mechanistic evidence demonstrate that intake of phytosterols (plant sterols) significantly reduces intestinal cholesterol absorption. Plant sterols achieve this primarily by displacing cholesterol from mixed micelles in the intestinal lumen and competing for intestinal uptake, leading to decreased net cholesterol absorption and lower circulating LDL cholesterol levels.

1:34:43Rhonda Patrick (host)supportedmoderate

Berberine lowers LDL cholesterol across clinical scenarios comparing it to placebo or statins.

"So there was a bunch of studies that looked at berberine and varying doses, and then looking at it in conjunction with statins or comparing it to statins or comparing it to a placebo. And it pretty much to me was convincing that it was beneficial in every single scenario. So berberine alone was lowering the LDL cholesterol" (said at 1:34:43)

Multiple systematic reviews and meta-analyses of randomized controlled trials demonstrate that berberine, alone or in combination, significantly reduces low-density lipoprotein (LDL) cholesterol and total cholesterol compared to placebo. When evaluated in conjunction with statins, berberine provides additive lipid-lowering effects, and head-to-head comparisons show lipid-modifying efficacy comparable to moderate-dose statins (e.g., simvastatin). However, systematic reviews consistently note that the overall quality of many included trials is low-to-moderate, warranting a moderate certainty rating.

1:35:30Peter Attiasupportedmoderate

Berberine acts as a mitochondrial Complex I inhibitor.

"Yeah, berberine is an analog of metformin, so it's a Complex I inhibitor." (said at 1:35:30)

Berberine acts as an inhibitor of mitochondrial respiratory chain Complex I (NADH:ubiquinone oxidoreductase). In vitro and isolated mitochondrial assays demonstrate that berberine dose-dependently inhibits cellular respiration via specific inhibition of Complex I, altering cellular energy ratios (such as AMP/ATP and NAD+/NADH) and triggering downstream metabolic effects such as AMPK activation and enhanced glycolysis. While berberine is a plant-derived isoquinoline alkaloid and structurally distinct from the biguanide metformin (meaning it is a functional rather than structural analog), its mechanism of inhibiting Complex I mirrors that of metformin.

1:36:20Rhonda Patrick (host)supportedlow

Berberine co-administration lowers the side effects of statin-induced myopathy and reduces the required effective statin dose to lower LDL cholesterol.

"And but what I do know is it also lowered the side effects of statin myopathy was one in particular. It lowered the effective dose of statins that was needed to lower the LDL cholesterol." (said at 1:36:20)

Clinical evidence and meta-analyses support that co-administering berberine with statins exerts complementary lipid-lowering effects, enabling patients to reach target low-density lipoprotein cholesterol (LDL-C) levels using lower doses of statins. Systematic reviews of randomized controlled trials (e.g., combining berberine with low-dose statins) demonstrate improved LDL-C lowering compared to monotherapy, while reducing the incidence of statin-associated adverse events such as muscle aches and transaminase elevations. However, certainty is low due to risk of bias and heterogeneity across the available trials.

1:39:41Peter Attiasupportedhigh

Red blood cells lack mitochondria and must use glucose for their metabolism.

"Now, of course my red blood cells demand it because they don't have mitochondria, so they're going to have to use glucose." (said at 1:39:41)

Mature mammalian erythrocytes (red blood cells) shed their nuclei and mitochondria during terminal erythroid differentiation. Lacking mitochondria, they cannot conduct oxidative phosphorylation or beta-oxidation of fatty acids and rely obligately on glucose metabolism via glycolysis for ATP production, as well as the pentose phosphate pathway for antioxidant defense.

1:41:59Peter Attiasupportedhigh

Muscle contraction triggers glucose transporter translocation to muscle cell surfaces independently of insulin.

"In a person who's particularly fit, there's also an insulin-independent system where just the contractile aspect of the muscle itself is enough to get glucose transporters up to the surface of the muscle." (said at 1:41:59)

Muscle contraction directly stimulates the translocation of glucose transporter type 4 (GLUT4) to the cell surface membrane in skeletal muscle through insulin-independent signaling mechanisms. These pathways involve intracellular calcium signaling (via CaMKII), mechanical/metabolic stress pathways, and AMP-activated protein kinase (AMPK). This contraction-mediated uptake is a fundamental physiological process that functions in healthy, sedentary, and insulin-resistant or type 2 diabetic individuals, though regular physical training further enhances muscle glucose handling capacity.

1:47:38Peter Attiasupportedmoderate

Age-related reductions in estrogen and testosterone impair glucose regulation and insulin sensitivity.

"So as we age, both the reduction in estrogen and testosterone impair this, hypercortisolemia impairs this, and then of course inactivity is the greatest thing that drives this." (said at 1:47:38)

Both estradiol (estrogen) and testosterone are potent regulators of glucose homeostasis and insulin sensitivity across sexes. As humans age, the decline in estrogen (notably during the menopausal transition) and testosterone contributes to adverse body composition changes—including increased visceral adiposity, muscle loss, and ectopic lipid deposition—as well as impaired muscle and hepatic insulin sensitivity, worsening glucose regulation.

1:49:50Peter Attiasupportedhigh

A hemoglobin A1c of 6.5% translates to an estimated average blood glucose level of 140 mg/dL.

"So diabetes is defined as a hemoglobin A1c above 6.5%. That translates—6.5% is an estimate of an average blood glucose of 140 milligrams per deciliter." (said at 1:49:50)

The standard linear regression formula established by the A1C-Derived Average Glucose (ADAG) study equates an HbA1c of 6.5% to an estimated average glucose (eAG) of approximately 140 mg/dL (specifically, 28.7 × 6.5 - 46.7 = 139.85 mg/dL). Furthermore, an HbA1c ≥6.5% is the universally accepted standard diagnostic threshold for diabetes.

1:55:07Peter Attiasupportedmoderate

World-class cyclists can sustain a power output of 4 to 4.3 watts per kilogram while keeping blood lactate below 2 mmol/L.

"A world-class cyclist is able to put out 4 watts per kilogram of power while keeping lactate below 2 millimole. In fact, the best cyclists in the world are probably at about 4.2, 4.3 watts per kilo." (said at 1:55:07)

Exercise physiology testing in world-class and professional endurance cyclists demonstrates exceptional mitochondrial oxidative capacity and lactate clearance, enabling them to sustain submaximal workloads of approximately 4.0 to 4.3 W/kg (often corresponding to the first lactate threshold, or Zone 2/FatMax) while maintaining blood lactate concentrations below 2.0 mmol/L, whereas moderately active individuals and non-athletes accumulate lactate at significantly lower power outputs.

1:46:37Peter Attiasupportedhigh

The hyperinsulinemic-euglycemic clamp technique is the gold standard method for measuring insulin sensitivity.

"what's called a euglycemic-insulin clamp, which is an experiment where you run IV glucose and IV insulin into people and you basically run a fixed amount of insulin into somebody and then determine how much glucose you need to put in to keep their glucose level fixed—that's called a euglycemic, keep glucose fixed—that's the gold standard for measuring insulin sensitivity." (said at 1:46:37)

The hyperinsulinemic-euglycemic clamp technique (first introduced by DeFronzo and colleagues) is universally recognized in clinical physiology and metabolic research as the reference gold standard for directly measuring in vivo insulin sensitivity and glucose disposal. The speaker's description of infusing a fixed dose of insulin alongside a variable intravenous glucose infusion to maintain euglycemia—where the required glucose infusion rate quantifies tissue sensitivity to insulin—is accurate.

1:47:38Peter Attiasupportedhigh

Hypercortisolemia impairs insulin sensitivity and glucose disposal.

"hypercortisolemia impairs this, and then of course inactivity is the greatest thing that drives this." (said at 1:47:38)

The claim that hypercortisolemia impairs insulin sensitivity and glucose disposal is well supported by clinical and physiological research. Studies using hyperinsulinemic-euglycemic clamp procedures in patients with Cushing's syndrome (chronic endogenous hypercortisolemia) demonstrate marked reductions in maximal glucose disposal and overall insulin sensitivity compared to healthy controls (PMID: 3905556, PMID: 6348064, PMID: 1769133). Furthermore, experimental administration of hydrocortisone in healthy individuals subjected to bed rest significantly decreases leg glucose uptake and induces skeletal muscle insulin resistance (PMID: 19919871).

1:50:42Peter Attiasupportedhigh

A hemoglobin A1c level of 5.0% corresponds to an average blood glucose level of approximately 100 mg/dL, while 5.5% corresponds to approximately 115 mg/dL.

"And what the hemoglobin A1c data would suggest is being at 5%, which is about an average of 100, is better than being at 5.5%, which is an average in the 115 range." (said at 1:50:42)

The speaker's conversion estimates closely match established empirical mathematical models relating glycated hemoglobin (HbA1c) to average blood glucose concentrations. In the A1C-Derived Average Glucose (ADAG) study, the validated regression formula (AG = 28.7 × HbA1c - 46.7) translates an HbA1c of 5.0% to approximately 97 mg/dL and 5.5% to approximately 111 mg/dL. In the earlier Diabetes Control and Complications Trial (DCCT) model (MPG = 35.6 × HbA1c - 77.3), an HbA1c of 5.0% corresponds to approximately 101 mg/dL and 5.5% to approximately 118 mg/dL. Across both models, 5.0% approximates 100 mg/dL and 5.5% falls within the 111–118 mg/dL range.

1:45:37Peter Attiasupportedmoderate

During the development of metabolic dysfunction, hyperinsulinemia emerges before fasting blood glucose levels become elevated.

"So before you see that elevated level of glucose, you will actually see an elevated level of insulin. So postprandial hyperinsulinemia is the metabolic harbinger of all this stuff." (said at 1:45:37)

Large prospective cohort and epidemiological studies demonstrate that during the pathogenesis of insulin resistance and type 2 diabetes, compensatory hyperinsulinemia and declining insulin sensitivity emerge years before overt fasting hyperglycemia develops. In longitudinal analyses such as the Whitehall II study, compensatory increases in insulin secretion and drops in insulin sensitivity were detectable 4 to 6 years before clinical diagnosis, whereas steep increases in fasting blood glucose only occurred closer to diagnosis once beta-cell compensation failed.

2:06:35Peter Attiasupportedmoderate

A 2018 JAMA study analyzed 120,000 subjects and a subsequent JACC study analyzed nearly 1 million subjects regarding cardiorespiratory fitness and mortality outcomes.

"That JAMA paper had 120,000 subjects in it. There was a JACC paper that came out a year ago that had almost a million subjects in it, and it showed the exact same findings." (said at 2:06:35)

The speaker's claim accurately describes two major published cohort studies. A 2018 study published in JAMA Network Open (Mandsager et al.) analyzed 122,007 patients undergoing treadmill testing and demonstrated a strong, graded inverse relationship between cardiorespiratory fitness and all-cause mortality. A 2022 study published in the Journal of the American College of Cardiology (Kokkinos et al.) examined 750,302 veterans ('almost a million subjects') and reported consistent findings across age, sex, and racial groups, confirming an inverse and graded relationship between fitness and mortality.

2:07:05Peter Attiasupportedmoderate

Comparing individuals in the bottom 25th percentile of VO2 max to those in the top 2.5% shows a hazard ratio of 5, representing a 400% greater all-cause mortality rate.

"the difference in risk between someone in the bottom 25 percentile of VO2 max to the top 2.5% has a hazard ratio of five, meaning it's 400% greater all-cause mortality if you're in the bottom 25% versus the top 2.5%." (said at 2:07:05)

A large retrospective cohort study of 122,007 adult patients undergoing treadmill testing (Mandsager et al., 2018) evaluated the relationship between cardiorespiratory fitness and long-term all-cause mortality. Patients were categorized by age- and sex-matched fitness performance into low (<25th percentile) and elite (≥97.7th percentile, or top ~2.3%). Comparing the lowest fitness group to elite performers revealed an adjusted hazard ratio of 5.04 (95% CI, 4.10–6.20; P < 0.001) for all-cause mortality, which directly corresponds to an approximate 400% higher hazard rate of death.

2:08:41Peter Attiasupportedhigh

Smoking is the number one modifiable risk factor for cancer, followed by obesity.

"Smoking is number one... Smoking is still the number one modifiable risk factor. What's after that? Obesity? GUEST1: Obesity, yep." (said at 2:08:41)

Epidemiological studies and population attributable fraction (PAF) analyses consistently identify cigarette smoking as the leading modifiable risk factor for cancer incidence and mortality, with excess body weight/obesity ranking second. In the United States (2019 data), cigarette smoking accounted for 19.3% of all incident cancer cases and 28.5% of cancer deaths, followed by excess body weight accounting for 7.6% of cases and 7.3% of deaths. Similar rankings are observed internationally, such as in the United Kingdom, where tobacco smoking accounted for 15.1% of cancer cases and overweight/obesity accounted for 6.3%.

2:13:18Peter Attiasupportedmoderate

Modifiable risk factors account for virtually the entirety of cardiovascular disease risk, but account for less than half of cancer risk.

"In cardiovascular disease, when we sit here and talk about modifiable risk factors like lipids, smoking, blood pressure, all these things, that virtually accounts for the entirety of the disease. In cancer, when we talk about the modifiable risk factors, it doesn't even account for half of it." (said at 2:13:18)

Large-scale epidemiological studies support both parts of the statement. In cardiovascular disease, the landmark 52-country INTERHEART study found that nine potentially modifiable risk factors (including abnormal lipids, smoking, hypertension, diabetes, and abdominal obesity) accounted for 90% of the population attributable risk of myocardial infarction in men and 94% in women. Conversely, comprehensive population attributable fraction analyses in the United States by the American Cancer Society (Islami et al., 2018 and 2024 updates) estimated that potentially modifiable risk factors (such as tobacco use, excess body weight, alcohol intake, poor diet, physical inactivity, UV radiation, and oncogenic infections) account for approximately 40% to 42% of all incident cancer cases and 44% to 45% of cancer deaths.

2:29:40Peter Attiasupportedmoderate

The Galleri liquid biopsy test from GRAIL has an overall sensitivity of roughly 20% for stage 1 and stage 2 breast cancers, but reaches 75% to 80% sensitivity for stage 1 and 2 ER/PR-negative breast cancers.

"if you look at breast cancer overall sensitivity, it's about 20% for stage one, stage two... But a closer look at the data showed that if you looked at ER/PR-negative breast cancers, stage one, stage two sensitivity was 75 to 80%. It was only in the triple positive—ER/PR-positive, HER2/neu-positive—that the sensitivity and specificity are so low." (said at 2:29:40)

Evidence from the Circulating Cell-free Genome Atlas (CCGA) development and validation studies (such as NCT02889978) indicates that targeted methylation cell-free DNA (cfDNA) testing (the Galleri platform) exhibits an overall low sensitivity for early-stage (stages I–II) breast cancer (approximately 15–25%), largely because circulating tumor fraction (cTAF) in early hormone receptor-positive disease is very low. However, circulating tumor fraction and assay sensitivity scale directly with tumor mitotic volume and proliferation rate (e.g., high Ki-67 index); consequently, detection sensitivity is substantially higher in more aggressive, highly proliferative subtypes such as ER/PR-negative and triple-negative breast cancers, reaching roughly 75–80% even in early stages.

2:32:50Peter Attiasupportedmoderate

Adenocarcinoma is the dominant type of lung cancer in non-smokers.

"Adenocarcinoma of the lung is the dominant cause of lung cancer in a non-smoker" (said at 2:32:50)

Published epidemiological and clinical data consistently demonstrate that adenocarcinoma is the predominant histological subtype of lung cancer in never-smokers. In meta-analytic and review literature, adenocarcinoma accounts for the vast majority of lung cancer cases in non-smokers (over 90% in screening cohorts).

2:10:44Peter Attiasupportedmoderate

Ectopic fat accumulation within the pancreas reduces the amount of insulin secreted by pancreatic beta cells.

"within the pancreas itself, where it serves the double role of not just creating an inflammatory environment, but also reducing the amount of insulin that the beta cell can release" (said at 2:10:44)

Clinical, histological, and interventional studies confirm that ectopic fat accumulation within the pancreas (intrapancreatic fat) induces metabolic and inflammatory stress that impairs beta-cell function and diminishes insulin secretion. In randomized and mechanistic studies (such as the Diabetes Remission Clinical Trial [DiRECT] and exercise intervention trials), increased pancreatic fat is associated with reduced first-phase and glucose-stimulated insulin secretion, whereas weight loss or exercise that reduces intrapancreatic fat content restores beta-cell secretory capacity.

2:24:06Peter Attiasupportedhigh

Standard colorectal cancer screening guidelines lowered the recommended starting age for average-risk individuals from 50 to 45.

"standard recommendations used to be every 10 years starting at 50; current recommendations are starting at 45." (said at 2:24:06)

The claim is accurate. In May 2021, the US Preventive Services Task Force (USPSTF) updated its guidelines for colorectal cancer (CRC) screening, expanding the recommendation to start at age 45 rather than age 50 for average-risk adults. Previously (in 2016), the USPSTF recommended routine screening starting at age 50.

2:25:25Rhonda Patrick (host)supportedhigh

The average lifetime risk of developing breast cancer for women is approximately 1 in 8.

"Now is that because there's a lifetime risk of 1 in 8 just on average, forget about all the—" (said at 2:25:25)

Standard epidemiological data and cancer registry statistics (such as the US Surveillance, Epidemiology, and End Results [SEER] program and UK cancer registries) establish that the average lifetime probability of a woman developing invasive breast cancer is approximately 12.5% to 13%, commonly expressed as approximately 1 in 8.

2:33:53Peter Attiasupportedmoderate

Radiation exposure exceeding 50 millisieverts per year is generally established to increase the risk of mutagenesis.

"Radiation is measured in units called millisieverts, and it's generally established that exposure to more than 50 millisieverts a year will increase your risk of mutagenesis." (said at 2:33:53)

Ionizing radiation exposure is quantified in sieverts (commonly millisieverts, mSv) to measure biological effective dose. Major radiation protection bodies, including the International Commission on Radiological Protection (ICRP) and national regulatory agencies, establish 50 mSv in a single year (and an average of 20 mSv per year over defined periods) as the maximum allowable occupational dose limit to constrain the stochastic risks of radiation-induced mutagenesis and carcinogenesis. Under standard radiobiological models, ionizing radiation causes DNA damage (such as double-strand breaks) that can result in somatic mutations and increase cancer risk.

2:34:10Peter Attiasupportedhigh

Living at sea level provides an environmental background radiation exposure of approximately 1 to 2 millisieverts per year.

"Living at sea level here in San Diego, just the exposure you get to the environment is about 1 to 2 millisieverts a year." (said at 2:34:10)

Standard dosimetric data from radiological protection authorities (such as UNSCEAR and the NCRP) indicate that annual effective exposure to natural environmental background radiation—consisting of cosmic radiation, terrestrial gamma radiation, ingested radionuclides, and inhaled radon—typically averages between 1 and 3 millisieverts (mSv) per year (with a worldwide population average of approximately 2.2 to 2.4 mSv per year). At sea level, direct cosmic radiation contributes roughly 0.3 to 0.4 mSv per year, with total natural exposure falling directly within the cited 1 to 2+ mSv/year range depending on local radon and soil radionuclide concentrations.

2:34:35Peter Attiasupportedmoderate

Coronary CT angiograms exposed patients to around 20 millisieverts of radiation 20 years ago, whereas modern CTAs deliver less than 1 millisievert.

"A CT angiogram 20 years ago was 20 millisieverts, 40% of your annual radiation allotment on one test. The last patient I sent for a CTA last week—because when we get the report it also shows the radiation—less than one millisievert." (said at 2:34:35)

The speaker's claim is supported by published clinical literature. Early coronary computed tomography angiography (CCTA) protocols, particularly retrospective ECG-gated techniques, delivered high radiation doses (often 10–20 mSv or more). Technological advances—such as prospective ECG-gating, high-pitch spiral acquisition, lower tube voltage, and iterative reconstruction algorithms—have reduced radiation exposure by roughly an order of magnitude, routinely achieving sub-millisievert (<1 mSv) effective doses in clinical practice.

2:41:10Peter Attiasupportedhigh

Administering unopposed estrogen without progesterone in women with an intact uterus increases the risk of endometrial hyperplasia and endometrial cancer.

"that in women with a uterus, failure to give progesterone with estrogen increases endometrial hyperplasia. So if you take a woman with a uterus and you just give her estrogen, but there's no progesterone, her endometrial lining will thicken, will thicken, will thicken, and as the endometrial lining gets thicker, so too goes the risk of hyperplasia and ultimately what's called dysplasia, which can lead to cancer. In other words, unopposed estrogen will increase the risk of endometrial cancer." (said at 2:41:10)

Extensive randomized controlled trial and observational evidence establishes that unopposed estrogen therapy in postmenopausal women with an intact uterus significantly increases the risk of endometrial hyperplasia and endometrial cancer. Cochrane systematic reviews of randomized trials show that unopposed estrogen substantially increases the odds of endometrial hyperplasia compared with placebo (OR 5.86 at 1 year and OR 8.97 after 1 year) or combined estrogen-progestogen therapy. Systematic reviews of clinical and epidemiological studies further confirm that chronic unopposed estrogen exposure is the primary hormonal risk factor for the progression from hyperplasia to endometrial carcinoma, and that adding a progestogen counteracts this proliferative effect.

2:42:15Peter Attiasupportedhigh

In the Women's Health Initiative trial, the conjugated equine estrogen (CEE) plus medroxyprogesterone acetate (MPA) arm was stopped early at ~5.5 years with a 0.1% higher absolute risk (5 vs 4 cases per 1,000 women) of breast cancer compared to placebo, with no difference in breast cancer mortality.

"And the study was looking at a number of outcomes, but it was terminated early at about 5 and a half years when it was noted that the women in the CEE plus MPA group versus the placebo had a 0.1% higher risk of developing breast cancer... It is true that in the CEE plus MPA group, that group had five cases of breast cancer per thousand women compared to four cases of breast cancer per thousand women in the placebo group, and it is true that that's a 25% increase in the relative risk, but of course the absolute risk is 0.1%. There was no difference in breast cancer mortality." (said at 2:42:15)

The Women's Health Initiative (WHI) randomized controlled trial evaluating combined conjugated equine estrogens (CEE) plus medroxyprogesterone acetate (MPA) vs placebo was stopped early after an average follow-up of 5.2 years (commonly cited as ~5 to 5.5 years) because the adverse boundary for invasive breast cancer was crossed and overall risks exceeded benefits. The study reported a relative risk increase of ~24-26% for invasive breast cancer (HR 1.26, 95% CI 1.00-1.59), corresponding to an absolute excess risk of 8 additional invasive breast cancers per 10,000 person-years (an absolute risk increase of 0.08% to 0.1% per year, or ~4 vs 5 per 1,000). Total and breast cancer-related mortality did not differ significantly during the intervention phase of the trial.

  • supports: Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal r… (JAMA 2002) · cited 15919x in the literature
    "On May 31, 2002, after a mean of 5.2 years of follow-up, the data and safety monitoring board recommended stopping the trial of estrogen plus progestin vs placebo because the test statistic for invasive breast cancer exceeded the stopping boundary for this adverse effect and the global index statistic supported risks exceeding benefits. ... Estimated hazard ratios (HRs) (nominal 95% confidence intervals [CIs]) were as follows: ... breast cancer, 1.26 (1.00-1.59) with 290 cases ... Absolute excess risks per 10 000 person-years attributable to estrogen plus progestin were 7 more CHD events, 8 more strokes, 8 more PEs, and 8 more invasive breast cancers ... All-cause mortality was not affected during the trial." (abstract, results and conclusions, passage verified)
    pubmedfull study (doi)
  • supports: Influence of estrogen plus progestin on breast cancer and mammography in healthy postmenop… (JAMA 2003) · cited 1870x in the literature
    "The Women's Health Initiative trial of combined estrogen plus progestin was stopped early when overall health risks, including invasive breast cancer, exceeded benefits. ... In intent-to-treat analyses, estrogen plus progestin increased total (245 vs 185 cases; hazard ratio [HR], 1.24; weighted P<.001) and invasive (199 vs 150 cases; HR, 1.24; weighted P =.003) breast cancers compared with placebo." (abstract, results)
    pubmedfull study (doi)
2:43:20Peter Attiasupportedhigh

At 19-year follow-up of the Women's Health Initiative CEE plus MPA trial, there remains no significant difference in breast cancer mortality compared to placebo.

"Those data, by the way, have been updated every decade or so, and we now have like 19-year follow-up on that group, and that fact still remains true to this day: there is still no difference in the mortality of breast cancer in the CEE plus MPA group." (said at 2:43:20)

Long-term follow-up data from the Women's Health Initiative randomized trials (published in 2020 with cumulative follow-up spanning approximately 20 years through December 2017) demonstrated that while conjugated equine estrogen (CEE) plus medroxyprogesterone acetate (MPA) was associated with an increased incidence of breast cancer (HR 1.28, 95% CI 1.13–1.45), there was no statistically significant difference in breast cancer mortality compared to placebo (71 deaths vs. 53 deaths; HR 1.35, 95% CI 0.94–1.95; P = 0.11).

2:43:40Peter Attiasupportedhigh

In the Women's Health Initiative trial, the CEE alone arm in women without a uterus had a lower incidence of breast cancer and lower breast cancer mortality compared to placebo.

"You saw that the CEE group alone had a lower incidence of breast cancer and eventually even a lower mortality due to breast cancer." (said at 2:43:40)

In the Women's Health Initiative (WHI) randomized clinical trial among postmenopausal women with prior hysterectomy (women without a uterus), conjugated equine estrogen (CEE) alone was associated with statistically significant reductions in both breast cancer incidence and breast cancer mortality compared to placebo over long-term (cumulative >20-year) follow-up.

  • supports: Association of Menopausal Hormone Therapy With Breast Cancer Incidence and Mortality Durin… (JAMA 2020) · cited 426x in the literature
    "CEE alone compared with placebo among 10 739 women with a prior hysterectomy was associated with statistically significantly lower breast cancer incidence with 238 cases (annualized rate, 0.30%) vs 296 cases (annualized rate, 0.37%; hazard ratio [HR], 0.78; 95% CI, 0.65-0.93; P = .005) and was associated with statistically significantly lower breast cancer mortality with 30 deaths (annualized mortality rate, 0.031%) vs 46 deaths (annualized mortality rate, 0.046%; HR, 0.60; 95% CI, 0.37-0.97; P = .04)." (abstract, results, passage verified)
    pubmedfull study (doi)
2:45:20Peter Attiasupportedhigh

Oral estradiol increases the risk of hypercoagulability compared to topical estradiol formulations.

"In terms of FDA-approved products, you have oral estradiol bioidentical. We don't use it because, frankly, there's a small but nonzero increase in the risk of hypercoagulability." (said at 2:45:20)

The literature confirms that oral estradiol administration is associated with a modest but statistically significant increased risk of venous thromboembolism and hypercoagulability due to first-pass hepatic metabolism, whereas transdermal (topical) estradiol avoids this first-pass effect and does not increase venous thromboembolism risk. A 2018 meta-analysis demonstrated that among women using estrogen-only hormone therapy, oral estrogen was associated with an increased risk of venous thromboembolism (relative risk 1.48, 95% CI 1.39–1.58), while transdermal preparations showed no increased risk (relative risk 0.97, 95% CI 0.87–1.09).

2:51:55Peter Attiasupportedhigh

Vaginal estrogen cream or suppositories alone ameliorate sexual symptoms but do not provide systemic bone protection or reduce vasomotor symptoms.

"Again, that won't give you any of the bone protection, that won't stop the night sweats or anything like that, but using vaginal estrogen products alone will at least ameliorate the sexual side effects." (said at 2:51:55)

Clinical consensus guidelines confirm that low-dose local vaginal estrogen products effectively relieve genitourinary syndrome of menopause (GSM), including vaginal dryness and sexual discomfort, but do not produce the systemic estrogen levels necessary to treat vasomotor symptoms (such as night sweats or hot flashes) or prevent postmenopausal bone loss. Systemic hormone therapy is required to achieve bone density protection and vasomotor symptom control.

2:59:18Peter Attiasupportedmoderate

Late initiation of hormone replacement therapy may increase Alzheimer's disease risk, while early initiation may potentially only benefit women with the APOE4 allele.

"The data right now suggest the following: late initiation of HRT may be counterproductive for AD risk, may actually increase AD risk. Um, early initiation appears to potentially only be beneficial in E4 women, but not E3 women." (said at 2:59:18)

The speaker's statement accurately summarizes the 'critical window' or 'timing hypothesis' and its modification by APOE genotype. Randomized trials like the Women's Health Initiative Memory Study (WHIMS) showed that initiating hormone replacement therapy (HRT) late in postmenopause (age 65+) increased dementia and cognitive impairment risk. Observational and imaging studies evaluate early initiation during the menopausal transition and consistently find that early initiation is associated with neuroprotective outcomes or reduced brain aging specifically in women with the APOE4 allele / high genetic risk for Alzheimer's disease, rather than non-carriers.

2:35:12Peter Attiasupportedhigh

A woman's lifetime risk of developing breast cancer is approximately 1 in 8.

"So it really makes zero sense for a woman who has a lifetime risk of 1 in 8, and perhaps even higher if she's obese and drinks alcohol, right..." (said at 2:35:12)

Standard epidemiological data from cancer surveillance registries (such as the National Cancer Institute's Surveillance, Epidemiology, and End Results [SEER] program) establish that the average cumulative lifetime risk for an American woman developing invasive breast cancer is approximately 12% to 13%, which equates to approximately 1 in 8 women.

2:37:24Peter Attiasupportedhigh

There is no FDA-approved drug product containing estriol in the United States.

"there is no FDA-approved estriol product. ... There is no FDA-approved product for estriol. So if a woman is taking estriol, which she's probably taking in a topical fashion in combination with estradiol, they usually refer to that as a Bi-Est. ... That is something that compounding pharmacies would have to make for a physician." (said at 2:37:24)

The speaker's statement is accurate. Estriol is not approved by the U.S. Food and Drug Administration (FDA) as a commercially manufactured drug product in the United States, although it is approved and prescribed in Europe. Consequently, patients in the United States seeking estriol-containing formulations (such as Bi-Est, a combination of estradiol and estriol) must obtain them as customized preparations from compounding pharmacies.

2:43:40Peter Attiasupportedhigh

Serum anti-Müllerian hormone (AMH) levels reflect a woman's remaining ovarian follicle reserve.

"Now, there's actually some interesting data that's looking at AMH levels, um, anti-Müllerian hormone, AMH. So this is basically telling you how many eggs you have left, how many follicles you have left." (said at 2:43:40)

The claim is supported by scientific evidence. Anti-Müllerian hormone (AMH) is secreted by granulosa cells of growing preantral and small antral follicles in the ovaries, and serum AMH levels correlate strongly with both antral follicle count (AFC) and the true histological count of primordial follicles (the remaining functional ovarian follicle pool/reserve). Studies, including direct histological quantification in premenopausal women undergoing oophorectomy, demonstrate that serum AMH positively correlates with primordial follicle density and serves as a reliable non-invasive biomarker for remaining ovarian reserve.

5:04:29Rhonda Patrick (host)supportedhigh

Nuclear steroid hormones such as estrogen, testosterone, and active vitamin D bind receptors that enter the cell nucleus to recognize response elements like EREs and VDREs and regulate gene expression.

"nuclear steroid hormones, I should say, sorry. So we have estrogen, testosterone, vitamin D is one. So these are these are binding to a receptor that, you know, in some cases the receptor complexes with other ones, it goes into the nucleus of a cell, which is where all the DNA is, and it goes down to the level of genes and it recognizes a little sequence of genes. So in the case of estrogen, it's called an estrogen response element, an ERE. In the case of vitamin D, it's called a VDRE, a vitamin D response element." (said at 5:04:29)

The host's description of the classical genomic action of steroid and secosteroid hormones is well supported. Lipophilic hormones such as estrogen and active vitamin D bind to specific intracellular receptors (such as the estrogen receptor and vitamin D receptor) that translocate or localize to the nucleus, heterodimerize or homodimerize, and recognize specific DNA regulatory sequences known as hormone response elements—specifically estrogen response elements (EREs) and vitamin D response elements (VDREs)—to control targeted gene transcription.

5:06:02Rhonda Patrick (host)supportedmoderate

Jumping rope increases bone mineral density.

"lots and lots of jumping rope, which there is evidence that that also builds bone density." (said at 5:06:02)

High-impact jumping exercises, including rope skipping, produce mechanical loading that stimulates bone remodeling and increases bone mineral density (BMD). Systematic reviews and meta-analyses of randomized and controlled trials demonstrate significant improvements in BMD at weight-bearing sites—particularly the femoral neck, total hip, and calcaneus—in both younger and older populations, though the effect is site-specific and generally smaller or non-significant at non-weight-bearing sites or the lumbar spine.

5:08:50Rhonda Patrick (host)supportedhigh

High levels of vitamin D increase the intestinal absorption of both dietary calcium and phosphorus.

"when you have a lot of vitamin D, you absorb more dietary calcium and you also absorb more phosphorus, and calcium plus phosphorus can precipitate, right?" (said at 5:08:50)

Established endocrine physiology demonstrates that active vitamin D (1,25-dihydroxyvitamin D / calcitriol) directly increases the intestinal absorption of both calcium and inorganic phosphate (phosphorus) by regulating mucosal transporters (such as TRPV6 and calbindin for calcium, and NaPi-IIb / Npt2b cotransporters for phosphate). Elevated levels of vitamin D augment the fractional intestinal absorption of both minerals.

5:11:52Peter Attiasupportedhigh

At least 100 to 200 mg of oral progesterone is required to adequately oppose estrogen at the endometrial level during hormone replacement therapy.

"You do need at least 100 milligrams to oppose the estrogen at the endometrial level, so, you know, somewhere between 100 and 200 is probably necessary." (said at 5:11:52)

The claim is supported by high-certainty randomized controlled trial and systematic review evidence. Standard clinical regimens for endometrial protection against estrogen-induced hyperplasia require oral micronized progesterone dosages of 100 mg daily (continuous regimen) or 200 mg daily for 12–14 days per month (sequential regimen). The Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial demonstrated that 200 mg/day of cyclic oral micronized progesterone effectively prevented endometrial hyperplasia compared to estrogen alone (PMID 8569016). Subsequent clinical reviews and systematic evaluations confirm that 100 mg daily continuously or 200 mg daily sequentially are the standard doses required for adequate endometrial protection (PMID 27277331, PMID 28251642).

5:12:20Peter Attiasupportedhigh

Natesto is an FDA-approved intranasal testosterone spray for testosterone replacement therapy in men.

"it's called Natesto, and it's a it's an intranasal testosterone spray that is FDA-approved for male use for testosterone replacement therapy" (said at 5:12:20)

Natesto is an intranasal testosterone formulation (a nasal gel delivered via a metered nasal applicator) approved by the US FDA for testosterone replacement therapy in adult males with conditions associated with a deficiency or absence of endogenous testosterone (hypogonadism).

5:13:57Peter Attiasupportedmoderate

Male testosterone levels peak in the 20s and decline gradually starting in the 20s and 30s.

"male testosterone probably peaks in the 20s and it's just a slow, steady decline. It's not um it's not like in the case of women where they, you know, they go through puberty, they have these hormones that are cyclical, and then fall off a cliff. With men, it sort of you go through puberty, you kind of peak, and then you're on a slow uh decline down." (said at 5:13:57)

Large-scale cohort and longitudinal studies of male endocrine physiology confirm that testosterone levels in healthy males typically peak in early adulthood (late adolescence to the 20s) and subsequently experience a slow, progressive decline throughout adult life. In longitudinal evaluations such as the Massachusetts Male Aging Study, total testosterone levels declined by approximately 1% to 1.6% per year in middle-aged and older men, with bioavailable testosterone declining by roughly 2% to 3% per year. Unlike the abrupt cessation of ovarian hormone production seen in female menopause, male androgen decline is gradual and continuous across decades.

5:17:14Peter Attiasupportedmoderate

Lower endogenous testosterone levels are associated with a higher risk of high-grade prostate cancer.

"we know that the lower the testosterone, the higher the risk of high-grade prostate cancer." (said at 5:17:14)

Multiple prospective and retrospective clinical cohort studies demonstrate that lower serum total, free, or bioavailable testosterone levels are independently associated with an increased detection of high-grade prostate cancer (e.g., higher Gleason score or predominant Gleason pattern 4) and a greater risk of Gleason score upgrading upon radical prostatectomy.

5:17:20Peter Attiasupportedhigh

Testosterone replacement therapy does not increase the risk of prostate cancer.

"testosterone replacement therapy does not increase the risk of prostate cancer." (said at 5:17:20)

Multiple systematic reviews and meta-analyses of randomized controlled trials (RCTs), as well as large-scale clinical trials such as the TRAVERSE trial, show that testosterone replacement therapy (TRT) in hypogonadal men does not increase the risk or incidence of prostate cancer or clinically significant prostate cancer compared to placebo.

5:18:11Peter Attiasupportedhigh

5-alpha reductase inhibitor drugs block the enzymatic conversion of testosterone to dihydrotestosterone (DHT).

"you can take a 5-alpha reductase inhibitor, uh so those are drugs that block the conversion of testosterone to dihydrotestosterone, which is a more potent androgen, and that's the that's the androgen that's driving androgen-specific hair loss." (said at 5:18:11)

The speaker accurately describes the biochemical mechanism of 5-alpha reductase inhibitors (such as finasteride and dutasteride) and their therapeutic role in androgenetic alopecia. Steroid 5-alpha reductase enzymes catalyze the conversion of testosterone into dihydrotestosterone (DHT), a potent androgen that drives follicle miniaturization in androgenetic alopecia. By inhibiting these enzymes, 5-alpha reductase inhibitors lower DHT levels and mitigate androgen-driven hair loss.

3:15:10Peter Attiasupportedhigh

Physiologic testosterone replacement in women typically uses approximately one-tenth the dose required for physiologic testosterone replacement in men.

"What we're talking about is replacing women to the levels that they were at in their 30s and 40s. These are very, very low levels of testosterone, uh typically about one-tenth the dose that men take to also have a physiologic replacement" (said at 3:15:10)

Clinical guidelines and expert consensus for androgen therapy in women state that physiologic testosterone replacement aims to restore serum concentrations to those of healthy young/premenopausal women. When using male transdermal testosterone formulations off-label for women, the appropriate dosing is approximately one-tenth of the standard adult male replacement dose (e.g., approximately 5 mg daily transdermal testosterone for women compared to 50 mg daily for hypogonadal men) to keep levels within the normal female physiological range without causing symptoms of androgen excess.

3:07:15Peter Attiasupportedmoderate

Testosterone replacement therapy can potentially increase prostate size and exacerbate benign prostatic hyperplasia (BPH).

"what it does do is potentially increase uh BPH, benign prostatic hypertrophy, so it does increase the size of the prostate potentially." (said at 3:07:15)

Testosterone replacement therapy (TRT) in hypogonadal men is associated with a modest, potential increase in prostate volume and growth rate (often restoring prostate tissue toward normal eugonadal levels). Longitudinal and clinical studies confirm a small, statistically significant increase in prostate growth rate with TRT, although this enlargement rarely leads to clinically meaningful worsening of lower urinary tract symptoms (LUTS) or International Prostate Symptom Scores (IPSS) in men without severe baseline obstruction.

3:08:15Peter Attiasupportedhigh

Dihydrotestosterone (DHT) is a more potent androgen than testosterone and drives androgenetic alopecia.

"dihydrotestosterone, which is a more potent androgen, and that's the that's the androgen that's driving androgen-specific hair loss." (said at 3:08:15)

Published literature strongly supports that dihydrotestosterone (DHT) is a significantly more potent androgen than testosterone and serves as the primary androgen driving follicle miniaturization in androgenetic alopecia (pattern hair loss). In genetically susceptible hair follicles, testosterone is converted locally to DHT by 5-alpha reductase enzymes (predominantly type 2). DHT binds to the androgen receptor with higher affinity than testosterone and alters paracrine signalling in dermal papilla cells, causing progressive miniaturization of terminal hairs into vellus hairs. The critical role of DHT is further demonstrated by the clinical efficacy of 5-alpha reductase inhibitors (such as finasteride and dutasteride) in halting and reversing androgenetic alopecia.

3:35:33Peter Attiasupportedhigh

Asymmetric dimethylarginine (ADMA) and symmetric dimethylarginine (SDMA) directly and indirectly inhibit nitric oxide synthase.

"ADMA and SDMA directly and indirectly inhibit nitric oxide synthase." (said at 3:35:33)

The statement is supported by established biochemical literature. Asymmetric dimethylarginine (ADMA) is a direct competitive inhibitor of nitric oxide synthase (NOS) enzymes, competing with L-arginine at the catalytic site. In contrast, symmetric dimethylarginine (SDMA) does not directly inhibit NOS enzyme kinetics, but indirectly inhibits nitric oxide synthesis by competing with L-arginine for cellular uptake via cationic amino acid transporters (y+ system), thereby reducing substrate availability for NOS.

3:35:42Peter Attiasupportedmoderate

Elevated homocysteine levels are associated with poor outcomes in cardiovascular disease.

"We know that homocysteine is associated with poor outcomes in cardiovascular disease" (said at 3:35:42)

Observational studies and meta-analyses support the claim that elevated plasma homocysteine levels are associated with adverse outcomes in patients with cardiovascular disease. Meta-analyses of prospective studies show that higher homocysteine levels in patients with acute coronary syndrome (ACS) or undergoing percutaneous coronary intervention (PCI) are significantly associated with an increased risk of major adverse cardiovascular events (MACE), all-cause mortality, and cardiac death. While randomized trials evaluating homocysteine-lowering therapies (e.g., B-vitamins) have shown mixed results regarding clinical benefit, the epidemiological and prognostic association between elevated homocysteine and poor cardiovascular outcomes is well established.

3:35:53Peter Attiasupportedhigh

Cocoa flavanols increase nitric oxide synthase activity in the endothelium.

"when you directly inhibit nitric oxide synthase in the endothelium, you are preventing the creation of nitric oxide. And of course, that's what cocoa flavanols actually do the opposite of that. So I think the one-two punch of lowering homocysteine and raising uh nitric oxide synthase activity via cocoa flavanols could could certainly explain a reduction in blood pressure." (said at 3:35:53)

Cocoa flavanols, particularly (-)-epicatechin, have been shown in multiple mechanistic and clinical studies to increase endothelial nitric oxide synthase (eNOS) activity and downstream nitric oxide (NO) production. In human endothelial cell models, flavanol exposure triggers eNOS activation via specific phosphorylation events (such as Ser633 and Ser1177) and association with calmodulin. Systematic reviews and clinical trials further demonstrate that cocoa flavanols stimulate endothelial nitric oxide synthesis and induce vasodilation, resulting in statistically significant reductions in blood pressure.

3:37:15Peter Attiasupportedhigh

Arm position significantly alters blood pressure readings on automated cuffs, such that placing an arm above the head versus at the level of the right atrium produces a large difference in measured pressure.

"if anybody wants to do this experiment at home, it's really interesting to do: put a put an automated cuff on your arm and put your arm here, put your arm above your head, and put your arm in the right spot, and look at how big a difference you get." (said at 3:37:15)

Arm position has a well-established and clinically meaningful effect on blood pressure readings measured by automated cuffs. In clinical trials evaluating arm positioning during blood pressure measurement, deviating from standard placement at heart level significantly alters recorded values due to hydrostatic pressure effects: placing the arm below heart level substantially increases readings (e.g. by 4 to 7 mm Hg when resting on the lap or hanging at the side), while placing the arm above heart level proportionally decreases measured pressure.

3:44:46Rhonda Patrick (host)supportedmoderate

Modifiable lifestyle factors, including exercise, nutrition, and supplementation, enhance cognitive function and neuroprotection partially through increases in brain-derived neurotrophic factor (BDNF) levels.

"This guide explores modifiable lifestyle factors, the tactics, strategies, and things you can do, particularly when it comes to exercise, nutrition, and even supplementation, to improve cognition and enhance neuroprotection, many of which are at least partially mediated through increases in brain-derived neurotrophic factor levels." (said at 3:44:46)

Extensive literature from human clinical trials, observational studies, and narrative/systematic reviews supports the claim that modifiable lifestyle interventions—specifically physical exercise, dietary strategies, and targeted supplementation—can enhance cognitive function and neuroprotection, with brain-derived neurotrophic factor (BDNF) upregulation serving as a primary mediating mechanism. Comprehensive reviews confirm that physical exercise (endurance, HIIT, and resistance training) and dietary interventions activate neuroprotective pathways including the PGC-1α/FNDC5/irisin signaling cascade, which leads to increased BDNF levels and subsequent improvements in synaptic plasticity, neurogenesis, and cognitive performance.

Unverified means no publication matching the claim was located; it does not prove the claim false. Spotted an error? See the corrections policy - disputes from the people quoted are prioritized.